Akèy › Leukemi › Texas › Houston
Etid klinik pou Leukemi nan Houston, TX
28 etid pou Leukemi ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Ap rekriteFaz 3
- Quetzal Site 6, Houston
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Ap rekriteFaz 1
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Ap rekriteFaz 2
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Ap rekriteFaz 3
- Research Site, Houston
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Ap rekriteFaz 1
- Texas Children's Hospital, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- University of Texas, Houston
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Ap rekriteFaz 1/2
- Research Site, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Ap rekriteFaz 2
- Baylor Texas Children's Hospital, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Ap rekriteFaz 2
- University of Texas MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Revumenib and Mezigdomide in People With Leukemia
Ap rekriteFaz 1/2
- MD Anderson Cancer Center (Data Collection Only), Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Ap rekriteFaz 1/2
- Dren Investigational Site, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
- Texas Children's Hospital, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Ap rekriteEtid obsèvasyon
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Ap rekriteFaz 2/3
- MD Anderson Cancer Center, Houston
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Ap rekriteFaz 1
- The University of Texas M.D. Anderson Cancer Center, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Etid Leukemi nan lòt vil
- Boston, MA25 etid
- New York City, NY19 etid
- Los Angeles, CA16 etid
- Chicago, IL16 etid
- Durham, NC13 etid
- Baldwin Park, CA12 etid
- Columbus, OH12 etid
- Nashville, TN12 etid
- Philadelphia, PA12 etid
- Seattle, WA11 etid
- Milwaukee, WI11 etid
- Birmingham, AL10 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)122 etid
- Kansè Metastatik104 etid
- Kansè kolorektal103 etid
- Kansè ovè90 etid
- Leksemi mieloïd egi86 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt69 etid
- Kansè pankreyas62 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.